Global Benign Prostatic Hyperplasia Market Growth (Status and Outlook) 2024-2030

Global Benign Prostatic Hyperplasia Market Growth (Status and Outlook) 2024-2030

Benign prostatic hyperplasia (BPH) also known as benign prostatic hypertrophy is characterized by the unusual propagation of the prostatic cells, which causes difficulties like urinary retention and infections of the urinary tract. It is most common among the aging men population, primarily driving this market. On the basis of geographical analysis, the North American region is expected to retain its dominance in this market owing to better healthcare infrastructure, high healthcare expenditure on urological disorders, increased awareness in the society increasing the outpatients center and hospitals visits.

The global Benign Prostatic Hyperplasia market size is projected to grow from US$ 10000 million in 2023 to US$ 14050 million in 2030; it is expected to grow at a CAGR of 5.0% from 2024 to 2030.

LPI (LP Information)' newest research report, the “Benign Prostatic Hyperplasia Industry Forecast” looks at past sales and reviews total world Benign Prostatic Hyperplasia sales in 2023, providing a comprehensive analysis by region and market sector of projected Benign Prostatic Hyperplasia sales for 2024 through 2030. With Benign Prostatic Hyperplasia sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Benign Prostatic Hyperplasia industry.

This Insight Report provides a comprehensive analysis of the global Benign Prostatic Hyperplasia landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Benign Prostatic Hyperplasia portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Benign Prostatic Hyperplasia market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Benign Prostatic Hyperplasia and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Benign Prostatic Hyperplasia.

United States market for Benign Prostatic Hyperplasia is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Benign Prostatic Hyperplasia is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Benign Prostatic Hyperplasia is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Benign Prostatic Hyperplasia players cover Abbott, Allergan, Astellas Pharma, Boehringer Ingelheim Pharma and Eli Lilly and Company, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Benign Prostatic Hyperplasia market by product type, application, key players and key regions and countries.

Segmentation by type
Drug Therapy
Dialysis
Others

Segmentation by application
Hospitals
Clinics

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott
Allergan
Astellas Pharma
Boehringer Ingelheim Pharma
Eli Lilly and Company
GlaxoSmithKline
Merck
Pfizer
Sanofi

Please note: The report will take approximately 2 business days to prepare and deliver.